Home
NewsNewsLatest development marks a transformative step in endometriosis care by reducing diagnostic delays and enabling earlier treatment for improved patient outcomes. ENDOSURE's rapid and accurate diagnostic capability is expected to benefit thousands of women suffering from this chronic condition across Canada.
EndoDiagnosis has announced that CReATe Fertility is the first clinic in Canada to offer the innovative Tier 1 ENDOSURE diagnostic test for endometriosis, authorized by Health Canada since 2021. This non-invasive diagnostic test provides an accurate and rapid alternative to the traditional gold standard of laparoscopic surgery for diagnosing endometriosis, a chronic and often debilitating inflammatory disease affecting women globally.
The ENDOSURE test offers 99% accuracy, delivering results within 30 minutes during a single clinic visit without the need for referrals or laboratory processing. It detects all types and stages of endometriosis and is suitable for women of all ages, from pre-teens to post-menopausal individuals. This enables healthcare providers to quickly confirm endometriosis as the cause of menstrual or abdominal pain and infertility, which are common symptoms of the disease.
Endometriosis affects at least 10% of women worldwide, yet diagnosis is often delayed by 3 to 11 years due to the limitations and invasiveness of laparoscopy. Many patients endure prolonged suffering without accurate diagnosis because symptoms overlap with other conditions, and pain is sometimes dismissed by clinicians or attributed to normal menstrual discomfort. Tier 1 diagnostic testing like ENDOSURE addresses this diagnostic gap by providing a reliable, pain-free, and fast diagnostic option.
By incorporating ENDOSURE, CReATe Fertility is leading the way in Canadian reproductive healthcare to accelerate diagnosis and treatment. Early identification of endometriosis is critical as it allows for timely symptom management and interventions that can slow or stop disease progression and improve fertility outcomes. The ability to diagnose in real time also helps clinicians monitor patient responses post-treatment and adjust care plans accordingly.
The offering of the Tier 1 ENDOSURE test at CReATe Fertility empowers both patients and healthcare providers with a decision-support tool that transforms the experience of care. Patients gain faster access to answers, reducing years of uncertainty and enabling better quality of life. Clinicians receive actionable diagnostic data to guide personalized treatment pathways without the risks or costs associated with surgery.
This move is part of EndoDiagnosis’ broader mission to revolutionize endometriosis care worldwide by making rapid, accurate, and non-invasive diagnostics accessible. The company supports providers with education and a network to facilitate the adoption of ENDOSURE. With the introduction of this test in Canada, women suffering from chronic pelvic pain and infertility symptoms now have access to state-of-the-art diagnostics that validate their experiences and offer hope for better management.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
